Condition

Pancreatic Cancer

Find a Doctor

Eileen M. O'reilly

Memorial Solid Tumor Group
Oncology, Internal Medicine
Female
Practicing approx. 31 years

Bio


Eileen O'reilly is an Oncologist and an Internal Medicine specialist in New York, New York. Dr. O'reilly is a global expert in Pancreatic Cancer. She has been an author on 255 peer reviewed articles and participated in 3 clinical trials in the past 15 years. In particular, she has been an author on 154 peer reviewed articles and participated in 2 clinical trials regarding Pancreatic Cancer. She is licensed to treat patients in NY.

Contact

1275 York Ave
New York, NY 10065, US

Latest Advances


Latest Advance
Study
  • Condition: Untreated Metastatic Pancreatic Adenocarcinoma
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Gemcitabine/Nab-Paclitaxel With Necuparanib VS Gembcitabine/Nab-Paclitaxel With Placebo
  • Number of Patients: 110
  • Published —
The purpose of the study was to evaluate the addition of necuparanib or placebo to gemcitabine/nab-paclitaxel in untreated metastatic pancreatic ductal adenocarcinoma
Latest Advance
Study
  • Condition: Patients with a Germline BRCA Mutation and Metastatic Pancreatic Cancer
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Maintenance Olaparib
  • Number of Patients: 154
  • Published —
This study reported pre-specified health-related quality of life (HRQoL) evaluation of patients with metastatic pancreatic cancer treated with maintenance olaparib.
Latest Advance
Study
  • Condition: Pancreas Adenocarcinoma (PDAC) and Germline BRCA/PALB2 Mutation
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Gemcitabine and Cisplatin with or without Veliparib
  • Number of Patients: 50
  • Published —
This study investigated cisplatin and gemcitabine with or without veliparib in patients with germline BRCA1/2 or PALB2 pancreatic ductal adenocarcinoma (PDAC).
Latest Advance
Study
  • Condition: Patient with Pancreatic Adenocarcinoma Harboring an NTRK Gene Fusion
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Oral Tropomyosin Receptor Kinase (TRK) Inhibitor Larotrectinib
  • Number of Patients: 1
  • Published —
This care report discussesthe response of a metastatic CTRC-NTRK1 gene fusion-positive pancreatic ductal adenocarcinoma (PDAC) to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib and the eventual development of resistance to treatment.
Latest Advance
Study
  • Condition: Metastatic Pancreatic Cancer
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Olaparib
  • Number of Patients: 154
  • Published —
In this study, researchers evaluated the quality of life outcomes of using olaparib for the treatment of metastatic pancreatic cancer in persons with a BRCA mutation.
Latest Advance
Study
  • Condition: Resectable Pancreatic Adenocarcinoma
  • Journal: Annals of surgical oncology
  • Treatment Used: Gemcitabine and Erlotinib plus Pancreaticoduodenectomy
  • Number of Patients: 97
  • Published —
This study tested the safety and efficacy of using gemcitabine and erlotinib with a pancreaticoduodenectomy to treat patients with resectable pancreatic adenocarcinoma.
Latest Advance
Study
  • Condition: Metastatic Colorectal Cancer
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Physical Activity
  • Number of Patients: 1218
  • Published —
The study researched physical activity on the survival and progression of metastatic colorectal cancer.
Latest Advance
Study
  • Condition: Metastatic Pancreatic Cancer
  • Journal: Cancer medicine
  • Treatment Used: Nab-Paclitaxel, Gemcitabine, and Tarextumab
  • Number of Patients: 0
  • Published —
In this study, researchers evaluated the effectiveness of the combination of nab-paclitaxel, gemcitabine, and tarextumab for the treatment of metastatic pancreatic cancer.
Latest Advance
Study
  • Condition: Germline BRCA-Mutated Metastatic Pancreatic Cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Maintenance Olaparib
  • Number of Patients: 3315
  • Published —
This study evaluated the effectiveness of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy.
Latest Advance
Study
  • Condition: Gallbladder Carcinoma (GBCA)
  • Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association
  • Treatment Used: Surgical Management
  • Number of Patients: 675
  • Published —
This study described differences in presentation, surgery, chemotherapy strategy, and survival for patients with gallbladder cancer (GBCA) over two decades at a tertiary referral center.
Latest Advance
Study
  • Condition: Cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Rivaroxaban
  • Number of Patients: 1080
  • Published —
This study evaluated rivaroxaban for thromboprophylaxis in high-risk patients with cancer.
Latest Advance
Study
  • Condition: Advanced Pancreatic Cancer
  • Journal: BMC cancer
  • Treatment Used: Nanoliposomal Irinotecan with Fluorouracil (Nal-IRI?+?5-FU/LV)
  • Number of Patients: 56
  • Published —
This study evaluated the safety and effectiveness of nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI?+?5-FU/LV) in patients with advanced pancreatic cancer.
Latest Advance
Study
  • Condition: Metastatic Pancreatic Cancer
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Second-Line Therapy
  • Number of Patients: 0
  • Published —
This study updated incorporated new evidence related to second-line therapy for patients with metastatic pancreatic cancer who have experienced disease progression or intolerable toxicity during first-line therapy.

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 150
  • Start Date: November 6, 2019
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Biological
  • Participants: 120
  • Start Date: February 15, 2018
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors

Contact

1275 York Ave
New York, NY 10065, US

Affiliations

  • Memorial Hospital For Cancer And Allied Diseases

Credentials

  • Licenses
    Internal Medicine in NY
  • Board Certifications
    Medical Oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.